Signal management is a critical pillar of pharmacovigilance, aimed at identifying, evaluating, and acting upon new safety information related to medicinal products.    

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drug-related problems. 

Good Distribution Practices for the Veterinary Medicinal Products according to Commission Implementing Regulation (EU) 2021/1248 of 29 July 2021.

The Marketing Authorisation Holder shall have permanently and continuously at its disposal an appropriately qualified person responsible for pharmacovigilance in the EU (QPPV).

Current legislation requires that the application for marketing authorization (MA) for medicinal products for human use be accompanied by a readability test or bridging report of the Package Leaflet in order to prove its readability by the user/patient.

The future of pharmacovigilance is likely to involve a number of advancements and changes in the way that the safety of medications is monitored and evaluated.